Timothy J Henrich1, Daniel R Kuritzkes. 1. Division of Infectious Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. thenrich@partners.org
Abstract
PURPOSE OF REVIEW: This review provides an overview of HIV-1 entry inhibitors, with a focus on drugs in the later stages of clinical development. RECENT FINDINGS: Entry of HIV-1 into target cells involves viral attachment, co-receptor binding, and fusion. Antiretroviral drugs that interact with each step in the entry process have been developed, but only two are currently approved for clinical use. The small molecule attachment inhibitor BMS-663068 has shown potent antiviral activity in early phase studies, and phase 2b trials are currently underway. The postattachment inhibitor ibalizumab has shown antiviral activity in phase 1 and 2 trials; further studies, including subcutaneous delivery of drug to healthy individuals, are anticipated. The CCR5 antagonist maraviroc is approved for use in treatment-naïve and treatment-experienced patients. Cenicriviroc, a small-molecule CCR5 antagonist that also has activity as a CCR2 antagonist, has entered phase 2b studies. No CXCR4 antagonists are currently in clinical trials, but once daily, next-generation injectable peptide fusion inhibitors have entered human trials. Both maraviroc and ibalizumab are being studied for prevention of HIV-1 transmission and/or for use in nucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens. SUMMARY: Inhibition of HIV-1 entry continues to be a promising target for antiretroviral drug development.
PURPOSE OF REVIEW: This review provides an overview of HIV-1 entry inhibitors, with a focus on drugs in the later stages of clinical development. RECENT FINDINGS: Entry of HIV-1 into target cells involves viral attachment, co-receptor binding, and fusion. Antiretroviral drugs that interact with each step in the entry process have been developed, but only two are currently approved for clinical use. The small molecule attachment inhibitor BMS-663068 has shown potent antiviral activity in early phase studies, and phase 2b trials are currently underway. The postattachment inhibitor ibalizumab has shown antiviral activity in phase 1 and 2 trials; further studies, including subcutaneous delivery of drug to healthy individuals, are anticipated. The CCR5 antagonist maraviroc is approved for use in treatment-naïve and treatment-experienced patients. Cenicriviroc, a small-molecule CCR5 antagonist that also has activity as a CCR2 antagonist, has entered phase 2b studies. No CXCR4 antagonists are currently in clinical trials, but once daily, next-generation injectable peptide fusion inhibitors have entered human trials. Both maraviroc and ibalizumab are being studied for prevention of HIV-1 transmission and/or for use in nucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens. SUMMARY: Inhibition of HIV-1 entry continues to be a promising target for antiretroviral drug development.
Authors: Jacob Lalezari; Melanie Thompson; Priny Kumar; Peter Piliero; Richard Davey; Kristine Patterson; Anne Shachoy-Clark; Kimberly Adkison; James Demarest; Yu Lou; Michelle Berrey; Stephen Piscitelli Journal: AIDS Date: 2005-09-23 Impact factor: 4.177
Authors: Charles B Hicks; Pedro Cahn; David A Cooper; Sharon L Walmsley; Christine Katlama; Bonaventura Clotet; Adriano Lazzarin; Margaret A Johnson; Dietmar Neubacher; Douglas Mayers; Hernan Valdez Journal: Lancet Date: 2006-08-05 Impact factor: 79.321
Authors: Tom Melby; Michael Despirito; Ralph Demasi; Gabrielle Heilek-Snyder; Michael L Greenberg; Neil Graham Journal: J Infect Dis Date: 2006-06-02 Impact factor: 5.226
Authors: W David Hardy; Roy M Gulick; Howard Mayer; Gerd Fätkenheuer; Mark Nelson; Jayvant Heera; Natasa Rajicic; James Goodrich Journal: J Acquir Immune Defic Syndr Date: 2010-12-15 Impact factor: 3.731
Authors: Carolina Gutiérrez; Laura Díaz; Alejandro Vallejo; Beatriz Hernández-Novoa; María Abad; Nadia Madrid; Viktor Dahl; Rafael Rubio; Ana M Moreno; Fernando Dronda; José Luis Casado; Enrique Navas; María Jesús Pérez-Elías; Javier Zamora; Sarah Palmer; Eduardo Muñoz; María Ángeles Muñoz-Fernández; Santiago Moreno Journal: PLoS One Date: 2011-12-08 Impact factor: 3.240
Authors: Andrew W Woodham; Joseph G Skeate; Adriana M Sanna; Julia R Taylor; Diane M Da Silva; Paula M Cannon; W Martin Kast Journal: AIDS Patient Care STDS Date: 2016-07 Impact factor: 5.078
Authors: Sergey Pustylnikov; Rajnish S Dave; Zafar K Khan; Vanessa Porkolab; Adel A Rashad; Matthew Hutchinson; Frank Fieschi; Irwin Chaiken; Pooja Jain Journal: AIDS Res Hum Retroviruses Date: 2015-09-18 Impact factor: 2.205